ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ZYME Zymeworks Inc

6.43
0.00 (0.00%)
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price
Ask Price
News -
Company Name Stock Ticker Symbol Market Type
Zymeworks Inc ZYME NYSE Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 6.43 19:00:00
Open Price Low Price High Price Close Price Prev Close
6.43
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 6.43 USD

Zymeworks Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
450.11M 70.00M - 412.48M 124.34M 1.78 3.62
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Zymeworks News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ZYME Message Board. Create One! See More Posts on ZYME Message Board See More Message Board Posts

Historical ZYME Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Zymeworks Description

Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Your Recent History

Delayed Upgrade Clock